News
IMRA
--
0.00%
--
DJ Imara Is Maintained at Overweight by Morgan Stanley
Dow Jones · 15h ago
DJ Imara Price Target Cut to $34.00/Share From $35.00 by Morgan Stanley
Dow Jones · 15h ago
Morgan Stanley Maintains Overweight on Imara, Lowers Price Target to $34
Morgan Stanley analyst Matthew Harrison maintains Imara (NASDAQ:IMRA) with a Overweight and lowers the price target from $35 to $34.
Benzinga · 15h ago
IMARA (IMRA) Gets a Buy Rating from Leerink Partners
Leerink Partners analyst Joseph Schwartz maintained a Buy rating on IMARA (IMRA) today and set a price target of $42.00. The company's shares closed last
SmarterAnalyst · 18h ago
DJ Imara Price Target Cut to $42.00/Share From $59.00 by SVB Leerink
Dow Jones · 21h ago
DJ Imara Is Maintained at Outperform by SVB Leerink
Dow Jones · 21h ago
--Analyst Actions: SVB Leerink Adjusts Price Target on IMARA to $42 From $59, Maintains Outperform Rating
MT Newswires · 21h ago
Mid-Afternoon Market Update: Nasdaq Surges 150 Points; Calyxt Shares Slide
Toward the end of trading Friday, the Dow traded up 1.5% to 31,388.89 while the NASDAQ rose 1.18% to 12,874.20. The S&P also rose, gaining 1.62% to 3,829.59.
Benzinga · 3d ago
DJ Imara, Inc. CEO Rahul Ballal on Q4 2020 Results -- Earnings Call Transcript >IMRA
Dow Jones · 3d ago
SIFY, WTI, OPEN and EVFM among notable midday movers
Gainers: Second Sight Medical Products (EYES) +337%.AMTD International (HKIB) +27%.Sify Technologies Limited (SIFY) +26%.Boqii Holding Limited (BQ) +25%.ChromaDex Corporation (CDXC) +22%.W&T Offshore (WTI) +21%.Anchiano Therapeutics (ANCN) +18%.Purple Inno...
Seekingalpha · 3d ago
Second Sight Medical Products, XTL Biopharmaceuticals leads healthcare gainers; Evofem Biosciences, T2 Biosystems among major losers
Gainers: Second Sight Medical Products (EYES) +151%, XTL Biopharmaceuticals (XTLB) +42%, Nurix Therapeutics (NRIX) +9%, Auris Medical Holding (EARS) +5%, Anchiano Therapeutics (ANCN) +5%.Losers: Evofem Biosciences (EVFM) -34%, T2 Biosystems (TTOO) -25%, IM...
Seekingalpha · 3d ago
Imara shares fall after FY results, 2021 forecast
Imara shares slide ([[IMRA]] -18.6%) after the company reported full-year results and provided financial forecast for 2021.Net loss was $49.2M, or $3.53/share, for the year ended December 31, 2020, compared
Seekingalpha · 3d ago
The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 4)
Benzinga · 3d ago
10-K: IMARA INC.
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 3d ago
Imara EPS misses by $0.27; outlook
Imara (IMRA): FY GAAP EPS of -$3.53 misses by $0.27.Cash, cash equivalents and investments of $88.2M.FY21 guidance:  Research and development expenses in the range of $50M-55M; general and administrative expenses in
Seekingalpha · 3d ago
Imara Expects Cash, Cash Equivalents, Investments as of Dec 31 Sufficient to Fund Planned Ops Into Mid-2022 >IMRA
Imara Expects Cash, Cash Equivalents, Investments as of Dec 31 Sufficient to Fund Planned Ops Into Mid-2022 >IMRA
Dow Jones · 3d ago
Imara Expects FY21 Research and Development Expenses Will Range Between $50M and $55M >IMRA
Imara Expects FY21 Research and Development Expenses Will Range Between $50M and $55M >IMRA
Dow Jones · 3d ago
Imara 2020 Loss/Shr $3.53 >IMRA
Imara 2020 Loss/Shr $3.53 >IMRA
Dow Jones · 3d ago
Press Release: Imara Reports Full Year 2020 Financial Results and Business Highlights
Dow Jones · 3d ago
Imara Inc to Host Earnings Call
March 05, 2021 (ACCESSWIRE via COMTEX) -- NEW YORK, NY / ACCESSWIRE / March 5, 2021 / Imara Inc (NASDAQ:IMRA) will be discussing their earnings results in...
ACCESSWIRE · 3d ago
Webull provides a variety of real-time IMRA stock news. You can receive the latest news about Imara Inc through multiple platforms. This information may help you make smarter investment decisions.
About IMRA
Imara, Inc. is a clinical-stage biopharmaceutical company. The Company is developing and commercializing therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. The Company’s product pipeline include IMR-687, which is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease (SCD), and beta-thalassemia. Its IMR-687 is a selective, small molecule inhibitor of phosphodiesterase-9 (PDE9). The Company is conducting a Phase 2a clinical trial of IMR-687 in adult patients with SCD and a Phase 2b clinical trial for the treatment of patients with beta-thalassemia.